Оптимизация консервативного лечения миомы матки антипрогестеронами и оценка влияния проводимой терапии на качество жизни женщин

In: Вестник новых медицинских технологий · 2011 · W207013232
article OA: closed CC0
View on OpenAlex
AI-generated summary by gemini-2.5-flash-lite, 2026-08-11

Six months of Gynestril treatment at 12.5 mg daily halted uterine leiomyoma growth and improved quality of life in women of reproductive and premenopausal age.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

There are the results of six-month using of the medication Gynestril (in a dose of 12,5 mg once a day) within women with uterine leiomyoma both of reproductive age and premenopausal age. It was determined that this medication puts a stay on the tumor growth and improves women quality of life.

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK